RHOA G17V mutation
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BIO-RHOA-G17V |
|---|---|
| Type | Biomarker |
| Aliases | Мутація RHOA G17V |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-BCELL-2025 |
Biomarker Facts
| Biomarker type | gene_mutation |
|---|---|
| Mutation details | {"functional_impact": "loss_of_function (dominant-negative)", "gene": "RHOA", "hgvs_protein": "p.G17V", "variant_type": "missense"} |
| Measurement | MethodNGS panel covering RHOA codon 17 hot-spot Unitscategorical (positive | negative) |
| Actionability lookup | {"gene": "RHOA", "variant": "G17V"} |
| Related biomarkers | None declared |
Notes
AITL-defining marker: ~70% of AITL / nodal TFH-cell lymphomas carry RHOA G17V. Useful diagnostic-confirmation marker (with TET2/IDH2/ DNMT3A clonal hematopoiesis-like background). Not currently algorithm-driving — informational. Future: may stratify within AITL prognosis. Outside AITL: rare in other hematologic neoplasms (gastric cancer context different therapeutic framing).
Used By
Indications
IND-AITL-1L-CHOEP- IND-AITL-1L-CHOEPIND-AITL-1L-CHP-BV- IND-AITL-1L-CHP-BV
Questionnaires
QUEST-AITL-1L-STUB- Angioimmunoblastic T-Cell Lymphoma — first line